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Plasma kallikrein formed from prekallikrein (PK) produces bradykinin from kininogens 
and activates factor XII. Plasma PK is activated by factors αXIIa, βXIIa, or prolylcar-
boxypeptidase (PRCP). A cross-sectional investigation determined if there is an asso-
ciation of PRCP and KLKB1 polymorphisms with cardiovascular disease (CVD). DNA 
was obtained from 2243 individuals from the Prevention of Events with Angiotensin 
Converting Enzyme trial. Two PRCP SNPs, rs7104980 and rs2298668, and two KLKB1 
SNPs, rs3733402 and rs3087505, were genotyped. Logistic regression models were 
performed for history of diabetes, myocardial infarction, stroke, angina, angiographic 
coronary disease, CABG, intermittent claudication, percutaneous transluminal coronary 
angioplasty (PTCA), and transient ischemic attack. The PRCP SNP rs7104980 increased 
the odds of having a history of PTCA by 21% [odds ratio (OR) = 1.211; 95% confidence 
intervals (CI) =  (1.008, 1.454)]; P =  0.041, but was non-significant after Bonferroni 
correction. Alternatively, having the G allele for rs3733402 (KLKB1 gene) decreased the 
odds of having a history of angiographic coronary disease by 24% [OR = 0.759; 95% 
CI = (0.622, 0.927)]; P = 0.007 that was statistically significant (P < 0.01) after Bonferroni 
correction for multiple hypothesis testing. When the best-fit model based on the Akaike 
information criterion controlled for age, weight, gender, hypertension, and history of 
angina, the G allele of KLKB1 rs3733402 that is associated with less plasma kallikrein 
activity correlated with reduced history of CVD.
Keywords: cardiovascular disease, prekallikrein, KLKB1, prolylcarboxypeptidase, PRCP, high molecular weight 
kininogen
inTrODUcTiOn
Plasma prekallikrein (PK) is a zymogen whose enzyme plasma kallikrein is known to initiate and 
amplify factor XII activation on collagen and polyphosphates in plasma in the intravascular com-
partment to activate intrinsic blood coagulation. Formed plasma kallikrein is also the major enzyme 
to generate bradykinin from high molecular weight kininogen (HK) and to convert plasminogen 
Abbreviations: AIC, akaike information criterion; CVD, cardiovascular disease; KLKB1, plasma prekallikrein gene; PEACE, 
prevention of Events with Angiotensin Converting Enzyme Inhibition Trial; PK, plasma prekallikrein protein; PRCP, prolyl-
carboxypeptidase gene; PRCP, prolylcarboxypeptidase protein.
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to plasmin and single-chain urokinase to two-chain urokinase 
for fibrinolysis, C3 and C5 to C3a and C5a, respectively, in the 
complement system and prorenin to renin in the renin angioten-
sin system. There are several SNPs that have been recognized to 
impact PK function. KLKB1 rs3087505 is associated with venous 
thrombosis and this SNP is in linkage disequilibrium (LD) 
with two F11 SNPs (rs2036914, rs3756008) also associated with 
thromboembolism (1, 2). Also an exon 5 N124S polymorphism 
(rs3733402) in Apple domain 2 results in reduced PK complex 
formation to HK, its plasma, and cell membrane-binding protein 
(3–5), and this interferes with optimal PK activation and BK 
formation. Recent studies with klkb1−/− mice indicate that ani-
mals lacking klkb1 have delayed arterial thrombosis not due to 
reduced contact activation but due to reduced vessel wall tissue 
factor (6, 7). These combined studies suggest that PK contributes 
to vascular homeostasis. Infact, previous work by our own group 
demonstrated that elevated plasma PK correlates with accelerated 
vascular disease and proteinuria in a large population of diabetic 
patients (8, 9).
Prolylcarboxypeptidase (PRCP) is a membrane-associated 
serine protease that cleaves peptides where the penultimate 
position is a Pro-X bond (10, 11). As an exopeptidase, it has 
been recognized to degrade desArg9-bradykinin, angiotensin 
II and III, and α-melanocyte-stimulating hormone1–13 (10–12). 
We also have shown that it is a plasma PK activator when PK 
assembles on HK on endothelial and other cell membranes, 
suggesting that it is an endopeptidase as well (13–15). Genetic 
studies have identified an association between PRCP and essen-
tial hypertension and metabolic syndrome (16, 17). An exon 
SNP of PRCP (rs2298668, E112D) indicates risk for chronic 
hypertension and preeclampsia in an African-American 
patient population (18). In a Han Chinese population, it is 
associated with treatment resistance to an ACE inhibitor (19). 
In another study of Han Chinese subjects, the G allele of intron 
SNP rs7104980, but not rs2298668, is associated with essential 
hypertension [odds ratio (OR) = 1.98, 95% confidence intervals 
(CI) = 1.62–2.43, P = 0.3 × 10−10] (20). PRCP-deficient gene-
trap (prcpgt/gt) mice that have 25% PRCP normal protein levels in 
their organs are constitutively hypertensive and have a height-
ened risk for arterial thrombosis (21). Likewise, spontaneous 
hypertensive rats (SHR) compared to their control Wistar rats 
also have reduced PRCP in cardiac tissue (22). PRCP deficiency 
in mice is associated with increased vascular inflammation and 
reduced cell proliferation, angiogenesis, and wound repair from 
physical injury and ischemia reperfusion (23). Opposite to PK, 
the presence of PRCP reduces vascular inflammation and arte-
rial thrombosis.
In the present investigation, we asked if polymorphisms 
of PRCP and PK are associated with cardiovascular disease 
(CVD). In a single cross-sectional study, we show that the G 
allele for PRCP intronic rs7014980 associates with CVD but 
does not meet statistical significance. Alternatively, the minor 
G allele of an exonic SNP rs3733402 (N124S) of KLKB1 is 
significantly associated with reduced CVD. These data suggest 
that a selected KLKB1 SNP (rs3733402) mirrors the phenotype 
observed in patient studies with diabetes and on murine dele-
tions of klkb1 (7–9).
MaTerials anD MeThODs
Data collection
Plasma samples for our cross-sectional investigation below 
were provided from the Prevention of Events with Angiotensin 
Converting Enzyme (PEACE) Inhibition Trial that were in the 
NIH Biorepository BioLincc (https://biolincc.nhlbi.nih.gov/
home/) (24). In the original PEACE trial, all participants signed 
informed consent that was approved by their local IRBs for blood 
collection (24). The goal of the PEACE trial was to test whether 
ACE-inhibitor therapy would reduce the rate of non-fatal myo-
cardial infarction (MI), death from cardiovascular causes, or 
coronary revascularization in low-risk patients with stable coro-
nary artery disease and normal or slightly reduced left ventricular 
function (ejection fraction >40%). The criteria for selection in 
the PEACE trial were individuals >50  years old with evidence 
of coronary artery disease documented by one of the following 
three criteria: (1) MI >3 months from enrollment, (2) coronary 
artery bypass grafting (CABG) or percutaneous transluminal 
coronary angioplasty (PTCA) >3months from enrollment, and 
(3) obstruction of at least one luminal diameter >50% of at least 
one native vessel on coronary angiography, and toleration of the 
medication and >80% compliance with the medication (24). 
The cardiovascular phenotypes were defined in the PEACE trial 
and obtained from its data dictionary (24). The outcomes of the 
present analysis were compared with the baseline, pretreatment 
cardiovascular phenotype of the subjects. We determined if the 
present selected SNPs correlated with the mild cardiovascular 
phenotypes of the subjects of the PEACE trial.
The subsample of subject plasmas from the repository were 
de-identified from the individual donors but were linked by code 
to clinical information in the data dictionary (23). The samples 
that were provided by NHLBI BioLincc were chosen by random 
availability of 1 ml plasma aliquots for shipment. We obtained 
an exempt approval from the University Hospitals Case Medical 
Center IRB NHR-12-13. Two thousand two hundred forty-three 
(N = 2243) plasma samples from the PEACE trial were used for 
DNA isolation. DNA was extracted by the NucleoSpin Plasma XS 
technique (Macherey-Nagel, Inc.) yielding 0.03–0.1 μg/sample. 
The extracted DNA had whole-genome amplification using 
REPLI-g Mini Kit (Cat# 150023) (QIAGEN) to yield 10 mg/ml. 
DNA samples were quantified using Qubit DNA quantification 
assay and a Qubit 2.0 Fluorometer (Life Technologies).
As described above, two SNPs from PRCP that have been 
associated with hypertension, intronic rs7104980 (11:82864153) 
(20) and exonic rs2298668 (11:82853252) (E112D) (18, 19) were 
studied. Also, two SNPs from KLKB1 that have been associ-
ated with vascular function were chosen for study; rs3087505 
(Chromosome location, 4:186258332) (1, 2) from the 3′UT 
and exonic rs3733402 (4:186236880) (N124S) (3). All SNPs 
studied were listed as Illumina Golden Gate validated and ABI 
TaqMan genotyping assays were available for them. ABI TaqMan 
chemistry consists of two probes labeled with either VIC or 
FAM and a primer pair to detect the specific SNP. Genotyping 
these samples was performed according to the manufacturer’s 
protocol. Specifically, 3–5 μl aliquots, containing 5–10 ng of DNA 
were transferred from 96-well reservoir plates to 384-well assay 
TaBle 1 | individual characteristics of the studied population (N = 2243 
from the Peace trialb).
Variable level Frequency column 
percentage
Relative age Under 51 58 2.59
51–55 364 16.23
56–60 414 18.46
61–65 440 19.62
66–70 485 21.62
71–75 305 13.60
76–80 155 6.91
Over 80 22 0.98
Sex Male 1846 82.30
Female 397 17.70
Hypertensiona No 1661 74.05
Yes 582 25.95
Cigarette use Frequently 313 13.96
Rarely 1406 62.71
Never 523 23.33
History of diabetes No 1914 85.33
Yes 329 14.67
History of myocardial 
infarction
No 935 41.70
Yes 1307 58.30
History of stroke No 2152 95.99
Yes 90 4.01
History of angina No 658 29.35
Yes 1584 70.65
History of angiographic 
coronary diseasec
No 770 34.33
Yes 1473 65.67
History of CABG No 1435 63.98
Yes 808 36.02
History of intermittent 
claudication
No 2061 91.89
Yes 182 8.11
History of PTCA No 1263 56.33
Yes 979 43.67
History of TIA No 2170 96.75
Yes 73 3.25
aHypertension was defined as having systolic blood pressure greater or equal to 
140 mmHg and/or having diastolic blood pressure greater or equal to 90 mmHg (24).
bThe larger PEACE trial was comprised of 8290 patients; this study represents 27% of 
the overall total.
cHistory of angiographic disease means documented by coronary angiography.
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plates for each individual being genotyped. Multiple 384-well 
assay plates were generated; the DNA was dried down, the plates 
then sealed, and frozen until assayed. A 5 μl aliquot of Master 
Mix, Probe and Primer was robotically added to each well of a 
384-well plate previously plated with DNA. PCR (40 cycles) was 
carried out on an ABI GeneAmp PCR System 9700 Dual Head 
Instrument and endpoint reads were carried out using the ABI 
7900 Sequence Detection System (SDS). All assay mixtures were 
prepared in an amplicon-free room to avoid contamination. 
Data from each SNP were clustered using ABI’s SDS version 2.3 
Software and Genotyping Calls (Vic/Vic; Fam/Fam; Vic/Fam) 
were automatically made by the software. Each file was manually 
inspected to remove outliers. The error rate of each SNP not 
identifying the genotype of eight control DNA samples examined 
15 times over the course of the study was 6.9% for rs7104980, 
6.2% for rs3087505, 13% for rs2298668, and 7.4% for rs3733402. 
These rates are similar to other large-scale genetic epidemiology 
studies.
statistical analysis
Genotyping rates were calculated for each SNP across all indi-
viduals. Allele and genotype frequencies were calculated for 
each SNP. Hardy–Weinberg equilibrium (HWE) and pairwise 
LD were assessed using standard methods. A heatmap was 
used to determine if SNP rs3733402 is in LD with F11 SNPs 
rs2036914 and rs3756008, respectively. Unconditional logistic 
regression models assessed the association between candidate 
SNPs and various disease outcomes calculating ORs and 95% CI. 
For each candidate SNP, having the rarer allele was compared 
to not having the rarer allele. Other covariates included in the 
logistic regression models were age, weight, gender, hyperten-
sion status, history of diabetes, history of angina, and/or ciga-
rette use. Hypertension in the PEACE trial was defined as having 
systolic blood pressure greater or equal to 140  mmHg and/or 
having diastolic blood pressure greater or equal to 90  mmHg 
(24). This variable is user-defined specific for this investigation 
and different from the history of hypertension variable used 
in the PEACE trial. For cigarette use, the “rarely” and “never” 
categories were combined and compared against “frequent” 
cigarette use. Logistic regression models were then compared 
using specific −2 log likelihood values in order to calculate the 
Akaike information criterion (AIC) (25). The result with the 
smallest AIC was chosen as the best-fitting model. Multiple 
hypothesis testing was corrected by the Bonferroni correction 
method. All statistical analyses were performed using SAS ver-
sion 9.3 and R.
resUlTs
Frequencies
Patient characteristics are presented in Table  1. Ninety-two 
percent of the subjects in the control and treated groups of the 
PEACE trial were Caucasians. The mean age of the 2243 suc-
cessfully genotyped participants was 64 ± 8 years, female (18%), 
frequently smoked cigarettes (14%), and had a history of transient 
ischemic attack (TIA) (3%), stroke (4%), intermittent claudication 
(8%),  diabetes (15%), and CABG (36%). The majority of patients 
did have a history of angina (71%) and angiographic coronary 
disease (66%). These patient characteristics were similar to the 
overall PEACE study population (24). This subset study that 
represents 2243 out of the total 8290 patients in the overall 
PEACE study population (27% of total) had similar clinical 
characteristics as the PEACE trial with exception of the incidence 
of hypertension (current trial 25 vs. 45% in PEACE), history of 
PTCA (current trial 43 vs. 72% in PEACE), and history of MI 
(current trial 42 vs. 55% in PEACE) (24).
Allele and genotype frequencies are presented in Table 2 for 
the candidate SNPs in the PRCP and KLKB1 genes. Across all four 
SNPs, the frequency of undetermined genotypes ranged from 5.1 
to 8.4%. For rs7104980 in the PRCP gene, the less common allele 
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TaBle 2 | allele and genotype frequencies for the PRCP and KLKB1 snPs.
allele frequencies
gene snP allele count Frequency dbsnP hapmap ceU frequency
PRCP rs7104980 C 2197 0.525 0.553
G 1985 0.475 0.447
rs2298668 G 684 0.165 0.083
T 3460 0.835 0.917
KLKB1 rs3733402 A 2080 0.506 0.519
G 2028 0.494 0.481
rs3087505 A 438 0.103 0.088
G 3820 0.897 0.912
genotype frequencies
gene snP genotype count Frequency dbsnP hapmap ceU frequency
PRCP rs7104980 C/C 713 0.341 0.301
C/G 771 0.369 0.504
G/G 607 0.290 0.195
rs2298668 G/G 120 0.058 0.017
G/T 444 0.214 0.133
T/T 1508 0.728 0.850
KLKB1 rs3733402 A/A 670 0.326 0.302
A/G 740 0.360 0.434
G/G 644 0.314 0.264
rs3087505 A/A 70 0.033 0.018
A/G 298 0.140 0.142
G/G 1761 0.827 0.841
hardy–weinberg equilibrium (hWe) and linkage disequilibrium (lD) measures
gene Test for hWe linkage disequilibrium measures
snP chi-square P-value locus 1 locus 2 correlation 
coefficient
PRCP rs7104980 142.0634 9.999 × 10−5 rs7104980 rs2298668 0.372
rs2298668 102.6263 9.999 × 10−5
KLKB1 rs3733402 160.2745 9.999 × 10−5 rs3733402 rs3087505  0.277
rs3087505 124.2959 9.999 × 10−5
was G (44.7%) and the rarer genotype was the G homozygote 
(G/G) (29%). For rs2298668 in the PRCP gene, the less common 
allele was the G allele (8.3%) and the rarer genotype was the G 
homozygote (G/G) (5.8%). For rs3087505 in the KLKB1 gene, 
the less common allele was the A allele (10.29%) and the rarer 
genotype was the A homozygote (A/A) (3.3%). For rs3733402 in 
the KLKB1 gene, the less common allele was the G allele (48.1%) 
and the rarer genotype was G/G (31.4%).
assessment of hardy–Weinberg 
equilibrium and linkage Disequilibrium
The Hardy–Weinberg chi-square values for each SNP (HWE), as 
well as the LD correlation coefficients between each SNP per gene, 
were computed. Low P-values associated with the chi-square 
statistic for the HWE tests were observed that were the result of 
a large sample size, suggesting that the SNPs were in violation of 
HWE. This finding was due to having a statistical power large 
enough to detect small differences in this study that were not 
truly biologically meaningful. Hence, no SNPs were removed. In 
addition, both the allele and genotype frequencies for all tested 
SNPs were very similar to those from the dbSNP Hapmap CEU 
frequencies (Table 2). There were no SNPs in significant LD. The 
correlation coefficient between the two PRCP SNPs was 0.372, 
and the correlation coefficient between the two KLKB1 SNPs was 
0.277, which were both smaller than the cutoff value of 0.8 for 
assessing significant LD. In a previous study examining SNPs 
associated with venous thrombosis, KLKB1 SNP rs3087505 was 
found to be in LD with two F11 SNPs rs2036914 and rs3756008 
(1). We determined that KLKB1 SNP rs3733402 is not in LD with 
F11 SNPs rs2036914 and rs3756008, although the two F11 SNPs 
are in LD with each other (Figure 1).
logistic regression Models and Model 
selection
Initially, logistic regression models were run for various CVD-
associated outcomes, including history of diabetes, MI, stroke, 
angina, angiographic coronary disease, CABG, intermittent 
claudication, PTCA, and TIA. The “baseline” model controlled 
for patient age, weight, and gender (Table 3). No associations 
were found for the PRCP rs2298668 and KLKB1 rs3087505 
SNPs. Having the rare G allele compared to not having the G 
allele for rs7104980 (PRCP gene) increased the odds of hav-
ing a history of PTCA by 21% [OR = 1.211; 95% CI = (1.008, 
1.454); P  =  0.041]. Alternatively, having the rarer G allele 
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FigUre 1 | linkage disequilibrium heatmap for rs3733402 vs. F11 snPs. KLKB1 SNP rs3733402 is not in LD with F11 SNPs rs2036914 and rs3756008, 
although the two F11 SNPs are in LD with each other. The LD heatmap is gray between the KLKB1 and F11 genes and red within the F11 gene.
compared to not having the G allele for rs3733402 (KLKB1 
gene) decreased the odds of having a history of angiographic 
coronary disease by 24% [OR = 0.759; 95% CI = (0.622, 0.927); 
P = 0.007]. After correcting for testing multiple SNPs by the 
Bonferroni correction method, only SNP rs3733402 (KLKB1 
gene) was significantly associated with an outcome of having a 
history of angiographic coronary disease (adjusted P < 0.0125) 
(Table 3).
In order to better understand the potential association between 
having the G alleles for rs7104980 and rs3733402 and CVD, we 
calculated the −2 log-likelihood values in order to calculate 
the AIC to determine the best-fitting model (25). As shown in 
Table  4, the final model chosen for rs7104980, which had the 
lowest AIC, controlled for the baseline covariates (age, gender, 
and weight), hypertension, and history of angina. Having the G 
allele compared to not having the G allele for rs7014980 (PRCP 
6Gittleman et al. KLKB1 in Mild Cardiovascular Disease
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gene) increased the odds of having hypertension and a history of 
angina by 22% [OR = 1.220; 95% CI = (1.016, 1.467)]; P = 0.034, 
but this analysis was not statistically significant (P > 0.01) after 
Bonferroni correction. Alternatively, having the G allele compared 
to not having the G allele for rs3733402 (KLKB1 gene) decreased 
the odds of the baseline covariates, hypertension, and history of 
angina by 24% [OR = 0.762; 95% CI = (0.623, 0.931); P = 0.008], 
which was statistically significant (P ≤ 0.01) for multiple testing 
after Bonferroni correction.
DiscUssiOn
The present cross-sectional study suggests that a polymorphism 
in KLKB1 associated with reduced PK binding to HK leading 
to a less actable zymogen is associated with reduced CVD. 
However, we are cautious in over interpreting the results of this 
investigation because it has several limitations. The PEACE trial 
was performed on low-risk individuals with CVD who had 
stable coronary artery disease and normal or slightly reduced left 
ventricular function. The patient population was 82% male with 
the majority of patients between 51 and 70 years of age with only 
14% frequent smokers. The majority of patients did not have TIA, 
stroke, claudication, diabetes, hypertension, CABG, or PTCA. 
The present subset analysis of samples from the PEACE trial was 
similar in most ways, but actually had subjects with significantly 
reduced incidence of hypertension, PTCA, and MI. Since these 
three indicators are important disease markers of CVD, their 
reduction may have influenced the outcomes of the present 
studies. Overall, the present study examined a healthier subset 
of individuals with lower risk CVD than in the original PEACE 
trial itself.
Although there were no associations with the non-coding 
SNP associated with venous thrombosis, it is of interest that the 
KLKB1 exonic SNP, rs3733402 (N124S), was shown to be protec-
tive in the studied subjects for having a history of angiographic 
coronary artery disease (Table 3). Rs3733402 is not in LD with 
two F11 SNPs associated with venous thrombosis even though 
KLKB1 SNP rs3087505 from the 3′prime UT region is (1). The 
meaning of SNPs of different genes being in LD and associated 
with one disorder, such as venous thrombosis, is not known. The 
TaBle 4 | Model selection for the best fit for the association between snP rs7104980 (PrcP gene) and snP rs3733402 (KlKB1 gene) with hypertension 
and a history of diabetes, cigarette use, or angina.
covariate(s) added PrcP – rs7104980 KlKB1 – rs3733402
history of PTca history of angiographic coronary disease
Or 95% ci P-value −2 log l aic Or 95% ci P-Value −2 log l aic
Baselinea 1.211 (1.008, 1.454) 0.041 2814.923 2849.357 0.759 (0.622, 0.927) 0.007* 2605.204 2605.204
Baselinea + Hypertension 1.209 (1.007, 1.452) 0.042 2812.164 2847.677 0.761 (0.624, 0.930) 0.007* 2602.004 2604.004
Baselinea + Hypertension + Hx of diabetes 1.208 (1.006, 1.451) 0.043 2807.581 2847.455 0.760 (0.623, 0.928) 0.007* 2600.974 2604.974
Baselinea + Hypertension + Cigarette use 1.214 (1.011, 1.459) 0.038 2804.401 2845.804 0.763 (0.625, 0.931) 0.008* 2600.346 2604.346
Baselinea + Hypertension + Hx of angina 1.220 (1.016, 1.467) 0.034 2744.022 2720.286 0.762 (0.623, 0.931) 0.008* 2573.113 2577.113b
aBaseline model includes age, weight, and gender covariates only.
bLowest AIC value.
*Significant at the Bonferroni corrected P-value for assessing 5 total models = 0.05/5 = 0.01.
TaBle 3 | association of cardiovascular disease outcomes with snPs in the PRCP and KLKB1 genes controlling for age, weight, and gender.
Outcome PrcP KlKB1
rs7104980 rs2298668 rs3733402 rs3087505
Or 95% ci P-value Or 95% ci P-value Or 95% ci P-value Or 95% ci P-value
History of diabetes 0.934 (0.723, 1.207) 0.601 0.893 (0.675, 1.183) 0.432 1.054 (0.808, 1.376) 0.696 0.955 (0.689, 1.323) 0.782
History of MI 1.203 (0.998, 1.449) 0.052 1.036 (0.851, 1.263) 0.723 0.958 (0.793, 1.156) 0.652 1.098 (0.874, 1.381) 0.422
History of stroke 1.111 (0.713, 1.732) 0.642 1.013 (0.618, 1.660) 0.959 0.993 (0.623, 1.582) 0.975 0.856 (0.492, 1.487) 0.580
History of angina 0.957 (0.786, 1.166) 0.664 1.068 (0.864, 1.320) 0.541 1.054 (0.859, 1.292) 0.614 0.796 (0.617, 1.029) 0.081
History of angiographic 
coronary disease
1.062 (0.877, 1.286) 0.535 1.042 (0.848, 1.279) 0.698 0.759 (0.622, 0.927) 0.007* 0.847 (0.670, 1.071) 0.166
History of CABG 1.001 (0.828, 1.211) 0.988 1.064 (0.869, 1.303) 0.548 0.917 (0.756, 1.113) 0.381 1.076 (0.850, 1.361) 0.542
History of intermittent 
claudication
0.882 (0.636, 1.225) 0.454 1.135 (0.804, 1.604) 0.471 0.994 (0.710, 1.392) 0.971 0.888 (0.579, 1.362) 0.586
History of PTCA 1.211 (1.008, 1.454) 0.041 1.018 (0.836, 1.239) 0.860 1.094 (0.907, 1.319) 0.347 0.970 (0.772, 1.218) 0.792
History of TIA 0.691 (0.425, 1.125) 0.137 0.638 (0.345, 1.181) 0.153 0.847 (0.506, 1.419) 0.528 1.022 (0.542, 1.928) 0.946
SNP rs7104980: G allele compared to no G allele.
SNP rs2298668: G allele compared to no G allele.
SNP rs3733402: G allele compared to no G allele.
SNP rs3087505: A allele compared to no A allele.
*Significant at the Bonferroni corrected P-value correction for assessing four total SNPs = 0.05/4 = 0.0125.
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N124S polymorphism is in the Apple domain 2 of PK where 
HK binds (3, 26). Since the majority of plasma PK circulates in 
complex with HK and HK is a PK receptor on endothelial cells, 
the polymorphism of rs3733402 may be functionally important 
in vivo (4, 5). Rs3733402, a common polymorphism, is associated 
with reduced PK binding to HK (3). The polymorphism alters 
a PK glycosylation site that reduces its ability to bind to HK (3, 
26). PK’s ability to bind to HK is important to protect plasma 
kallikrein from inhibition by C1 inhibitor and for PK’s activation 
by PRCP on cells (5, 27). This polymorphism may promote C1 
inhibition of plasma kallikrein and reduce PRCP activation of 
PK to plasma kallikrein, thus limiting plasma kallikrein activity 
in two ways in vivo (27, 28).
Previous studies by us have shown that elevated plasma PK 
is associated with accelerated diabetic vascular disease (8, 9). 
Elevations of plasma kallikrein may be associated with increased 
prorenin conversion to renin and renin formation leading to 
elevated angiotensin II. Recent genome-wide meta-analysis stud-
ies indicate that the KLKB1 SNP rs3733402 has a positive cor-
relation with circulating B-type natriuretic peptide, a recognized 
cardioprotective vasodilator in African Americans (29). Other 
recent studies show that PK deficient mice (klkb1−/− mice) have 
reduced arterial thrombosis providing support in mouse models 
to enhance the observation made in human association studies 
(6–9). It is of interest that mechanism for delayed thrombosis in 
klkb1−/− mice is mediated in part through elevated prostacyclin 
and vasculo-protective transcription factors Sirt1 and KLF4 with 
reduction of vessel wall tissue factor and not reduced contact 
activation as is commonly believed (7). The results of the present 
investigation showing that rs3733402 is associated with decreased 
CVD are consistent with these other studies (8, 9). Combined 
these investigations suggest that lowered PK may improve vascu-
lar health indirectly by reducing vessel thrombosis risk.
In the present investigation, it might be construed that 
significance of rs3733402 with a history of angiographic 
coronary disease is not consistent with the results observed for 
intermittent claudication, PTCA, and angina (Table 3). The lack 
of association with intermittent claudication is not surprising 
because there was a very small group of individuals in the study 
population with this clinical problem. In a similar manner, one 
may argue that the population of study subjects with PTCA was 
also a smaller group than the angiographic coronary disease 
group. When a logistic regression study was performed with a 
baseline model, including age, weight, gender, hypertension, 
and history of angina, history of angina did contribute to the 
best-fitting model (25) (Table 4).
The studies on PRCP SNPs were performed because PK is 
a substrate of PRCP. Furthermore, investigations show that an 
absence of PRCP in gene-trap mice is associated with CVD 
manifested as vascular inflammation, including increased ves-
sel leukocytosis, reactive oxygen species, and apoptosis with 
reduced cellular proliferation, constitutive anticoagulation, and 
vessel angiogenesis and repair after mechanical and ischemia/
reperfusion injury (21, 23). The current study suggests that the G 
allele of rs7104980 of PRCP may be a cardiovascular risk factor 
for PTCA, controlling for age, weight, and gender (P < 0.041), 
but the Bonferroni correction of the P-value for the total number 
of SNPs (P < 0.0125) shows non-significance (Table 3). Likewise 
the use of the AIC to choose the best-fitting result did not identify 
additional subsets such as hypertension or history of angina that 
increased the significance of this association (Table  4). In this 
population of patient with less severe CVD, we did not observe 
PRCP SNPs as risk factors. Our investigations were consistent 
with the investigations of Wu et al. who showed that the G allele 
of SNP rs710980 was associated with susceptibility for essential 
hypertension in 1020 Han Chinese (20). However, our present 
study has results that do not meet the significance level set by our 
investigations’ parameters. The implication of these data may be 
that polymorphisms in PRCP may be significant in patients with 
more serious hypertensive CVD than those investigated in the 
present study.
Furthermore, our studies like others did not show any sig-
nificant association with the rs2298668 PRCP polymorphism 
(E112D PRCP) that was associated with chronic hypertension 
with or without increased risk of preeclampsia or resistance to an 
ACE-inhibitor therapy for hypertension (18, 19). First, the studies 
of Wang et al. and Zhang et al. were with patients who had more 
advanced hypertension and signs of deteriorating cardiovascular 
health than the subjects examined in the present report (18, 19). 
This difference also accounts for the different results with SNP 
rs2298668 between these two studies and the one of Wu et  al. 
(18–20). The investigation of Wu et al. used subjects who just had 
essential hypertension without history of diabetes mellitus, MI, 
cerebrovascular accident, or other serious diseases (20). Finally, 
since previous studies with SNPs rs7104980 and rs2298668 were 
performed on Asian and African-Americans subjects, respec-
tively, the non-statistically significant results observed in the 
present study also may be related to the mostly male Caucasian 
population examined.
When we performed this investigation, we were concerned 
whether we were able to get adequate DNA from stored plasma 
samples. We avoided serum samples for DNA preparation in 
this investigation since it has been associated with degraded 
DNA (30). We reasoned that well-collected plasma samples 
properly stored preserves soluble DNA for adequate preparation 
for assay like it does for study of blood coagulation zymogens. 
Our studies show that the genotyping error rate of 5–8.4% in the 
DNA prepared from subject plasma samples is less than that of 
6.2–13% error rate in control DNA prepared from tissue across 
the SNPs.
Another caution in interpreting these findings is that this 
investigation is based only on a single cross-sectional study of 
samples. It needs to be confirmed by similar investigations on 
additional sample sets. Furthermore, the results of this cross-
sectional study should be confirmed in a case-controlled study to 
obviate any unintended selection bias.
In sum, we postulate that the G allele of a KLKB1 SNP, 
rs3733402, is associated with reduced hypertension and 
coronary artery disease. These data suggest that reduction of 
PK activity may reduce CVD consistent with our previous 
studies in diabetic patients (8, 9). Our current findings also are 
consistent with our murine models. In our animal models, PK 
and PRCP may have opposing activities in the cardiovascular 
system regulating our risks for arterial disease. Reduction of PK 
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cOnclUsiOn
This paper is the first cross-sectional investigation on two KLKB1 
SNPs on a group of patients with mild CVD. When subject age, 
male gender, and weight are taken into account, KLKB1 SNP 
rs3733402 significantly associates with those with a reduced 
history of angiographic coronary artery disease. When subjects 
have covariates of age, weight, gender, hypertension, rs3733402 
best associates with those individuals who both have a reduced 
history of angina. Rs3733402, an exonic SNP that is associated 
with reduced PK activation, also is associated with reduced CVD.
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